A solubilisation product consists of resveratrol, polysorbate 80 and polysorbate 20, at least one medium-chain triglyceride, and tocopherol. The solubilisation product is for use as a pharmaceutical product. The solubilisation product can be used as a pharmaceutical product in the treatment of Alzheimer's disease, Friedreich's ataxia, lysosomal diseases, in particular Tay-Sachs disease, cancer, diabetes, atherosclerosis, heart diseases, arthritis or autoimmune diseases.